Reaching unprecedented outcome dimensions in malignant mesothelioma
Reaching unprecedented outcome dimensions in mal
Interview: “Survival is the result of multiple treatment lines”
Interview: “Survival is the result of multiple t
EGFR-mutant lung cancer: sequencing as a major topic in light of new data
EGFR-mutant lung cancer: sequencing as a major t
Randomised findings on CT-based follow-up after resection of early NSCLC
Randomised findings on CT-based follow-up after
Immunostimulation as a promising approach in SCLC
Immunostimulation as a promising approach in SCL
Immunotherapy: once more at the cutting edge of progress
Immunotherapy: once more at the cutting edge of
Preface – ESMO 2017
Preface – ESMO 2017 David R. Gandara, MD Pro
Potent treatment options in ALK– and MET-positive disease
Potent treatment options in ALK– and MET-positiv
Interview: Several reasons support sequencing of EGFR TKI treatment
Several reasons support sequencing of EGFR TKI t
EGFR-mutant lung cancer: what’s new with respect to activity and resistance?
EGFR-mutant lung cancer: what’s new with respect
